Stay updated on ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial
Sign up to get notified when there's something new on the ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial page.

Latest updates to the ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now displays the completed Phase 1 study record for enfortumab vedotin, with details on the trial’s purpose, treatment plan, eligibility, outcomes, and participating locations, rather than a forbidden-access error.SummaryDifference69%

- Check18 days agoChange DetectedThe ClinicalTrials.gov footer revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide banner announces an NIH transition notice about using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check32 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2 on the ClinicalTrials.gov 403 error page.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1, while the page continues to display a 403 error.SummaryDifference0.2%

- Check53 days agoChange DetectedThe study page now shows a 403 Forbidden message, replacing the usual content, and the Home link appears to be removed, indicating restricted access to the page.SummaryDifference0.5%

Stay in the know with updates to ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial page.